How IGF-1 LR3 Affects IGF-1

IGF-1 LR3 raises IGF-1 receptor activity by a different route from every GH-axis compound:

1. Direct delivery: LR3 is recombinant IGF-1 with an Arg3 substitution plus a 13-amino-acid N-terminal extension. You are injecting the hormone, not asking the liver to make it. There is no pituitary or hepatic step.
2. IGFBP resistance: The modifications reduce binding to the IGF-binding proteins roughly 1,000-fold (King et al., 1992). Native IGF-1 is over 99% bound and buffered; LR3 circulates as free, bioactive peptide, so each unit delivered reaches the IGF-1 receptor.
3. Suppression of the endogenous axis: Because circulating IGF-1 activity is high, the pituitary senses it and suppresses GH, which lowers your own liver-derived IGF-1 (Conlon et al., 1995). You are overriding the axis, not adding to it.
4. Assay ambiguity: Standard IGF-1 immunoassays may partly capture LR3 (the antibody can still bind it) or miss it depending on the assay (Niederkofler et al., 2013; Mongongu et al., 2021). A measured serum IGF-1 on cycle reflects an unknown mix of suppressed endogenous IGF-1 and cross-reacting exogenous LR3.

Important caveat: there is no human pharmacokinetic study of LR3 at bodybuilding doses, and the assay cross-reactivity means a serum number cannot be cleanly attributed to the drug versus your own axis.

What the lab may show:

• Serum IGF-1 may read elevated if blood is drawn while LR3 is still circulating and the assay cross-reacts
• Serum IGF-1 may read normal or even low if drawn after LR3 has cleared and the endogenous axis has been suppressed
• Neither reading proves the compound is or is not working

Reference anchors:

• Adult male serum IGF-1 (age 30-34) runs roughly 99-349 ng/mL (about 13-46 nmol/L); ranges decline with age
• The acromegaly diagnostic threshold is 1.3x the age-specific upper limit (Giustina et al., 2024). Any reading above that is a stop signal regardless of source.

Timeline: the community-quoted 20-30 hour half-life is structural reasoning, not measured; one rodent study found LR3 cleared faster than expected. Draw serum IGF-1 at least 72 hours after the last injection to estimate endogenous recovery.

Baseline: Obtain a fasted serum IGF-1 before the first injection, using an age-matched reference range, from the lab you will use throughout.

During use:

• Serum IGF-1 is the least interpretable marker on this compound, so do not over-read it. Use the same lab and draw consistently relative to your last injection.
• Treat any reading above 1.3x the age-specific upper limit as acromegalic territory and a reason to stop or reduce, whether the elevation is endogenous or assay cross-reactivity.

Post-cycle: Draw serum IGF-1 no sooner than 72 hours after the last injection to estimate how much your own axis has recovered.

Practical note: Because serum IGF-1 is ambiguous here, lean on the downstream markers that are interpretable: fasting glucose, fasting insulin, and HOMA-IR for metabolic effect, and ALT/AST plus cystatin-C-based eGFR for organ safety.

Do not chase a serum IGF-1 number on cycle: it cannot be cleanly attributed. Judge response on training, recovery and body composition, and judge safety on glucose and organ markers.

If serum IGF-1 is above 1.3x the age ULN: stop or cut the dose. Sustained supraphysiological IGF-1 is epidemiologically linked to organ growth and cancer risk.

Use the same lab every time: inter-assay variation alone can shift the same sample by up to 30%, on top of the LR3 cross-reactivity problem.

Running GH or MK-677 alongside makes IGF-1 uninterpretable: those raise endogenous liver IGF-1 on top of the injected LR3 signal. If you want a meaningful IGF-1 number, you cannot read it through a GH stack.